Transnasal Endoscopy Acquires Esophageal Biopsies Adequate for Comprehensive Pathology Evaluation in Patients With Eosinophilic Esophagitis.

Transnasal endoscopy (TNE) does not require general anesthesia, an attractive characteristic for monitoring eosinophilic esophagitis (EoE). We evaluated the adequacy of TNE-obtained esophageal biopsies using the EoE Histology Scoring System (EoEHSS). The Cincinnati Center for Eosinophilic Disorders database was searched for esophageal biopsies obtained by the same endoscopist, using either TNE or conventional endoscopy (CE). Whole-slide biopsy images were evaluated. The Mann-Whitney test was used for median (interquartile range) values and Fisher exact test for categorical variables. Median age ( TNE- and CE-obtained esophageal biopsies are similarly sufficient for evaluation of key pathological features in EoE.

Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: O.L.N. None. A.B. None. K.K. None. P.K. None. S.B. None. V.A.M. has been a consultant for Regeneron, Sanofi, Allakos, and Shire/Takeda; and serves on an adjudication committee for Alladapt. R.S. None. C.W. None. M.E.R. has received research support from AstraZeneca, Regeneron-Sanofi, GlaxoSmithKline, the CURED Foundation, the Food Allergy Fund, NIH grants, and a US–Israel Binational Grant (number 2019016); receives royalties from Ception Therapeutics (for reslizumab), Mapi Research Trust (for the Pediatric Eosinophilic Esophagitis Symptom Score version 2), and UpToDate; is a consultant for AstraZeneca, Bristol Myers Squibb, Regeneron-Sanofi, Revolo Biotherapeutics, Celldex, Nexstone One, and Guidepoint; has received payment for expert testimony from Tucker Ellis; is an inventor on patents owned by Cincinnati Children’s Hospital Medical Center; has a leadership role in the International Eosinophil Society; has equity interest in PulmOne Therapeutics, Spoon Guru, ClostraBio, Serpin Pharm, Celldex, Nextstone One, and Allakos; and has received equipment from Phadia. M.H.C. is a consultant for Allakos; Arena/Pfizer; AstraZeneca; Calypso Biotech; EsoCap Biotech; GlaxoSmithKline; Receptos/Celgene/Bristol Myers Squibb; Regeneron Pharmaceuticals; Robarts Clinical Trials, Inc./Alimentiv, Inc; and Shire, a Takeda company; and has received license fees for use of the Eosinophilic Esophagitis Histology Scoring System (EoEHSS).